Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort-Reference-Cited by-同舟云学术

Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort

Published:2018-07-31 Issue:1 Volume:18 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Huber Yvonne^ORCID,Bierling Franziska,Labenz Christian,Koch Sandra,Schmidtmann Irene,Kloeckner Roman,Schotten Sebastian,Huber Tobias,Lang Hauke,Woerns Marcus A.,Galle Peter R.,Weinmann Arndt,Weinmann-Menke Julia

Funder

Deutsche Forschungsgemeinschaft

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-018-4677-y.pdf

Reference31 articles.

1. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56(6):1384–91.

2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.

3. Colombo M, Sangiovanni A. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2015;35(Suppl 1):129–38.

4. Vauthey JN, Dixon E, Abdalla EK, Helton WS, Pawlik TM, Taouli B, Brouquet A, Adams RB. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010;12(5):289–99.

5. Lee YH, Hsu CY, Chu CW, Liu PH, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI. A new Child-Turcotte-Pugh class 0 for patients with hepatocellular carcinoma: determinants, prognostic impact and ability to improve the current staging systems. PLoS One. 2014;9(6):e99115.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum biomarker signature is predictive of the risk of hepatocellular cancer in patients with cirrhosis;Gut;2024-02-16

2. Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma;Journal of Hepatocellular Carcinoma;2022-10

3. Risk factors and pathogenic mechanism–associated hepatocellular carcinoma;Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma;2022

4. Dairy consumption and hepatocellular carcinoma risk;Annals of Translational Medicine;2021-04

5. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance;International Journal of Molecular Sciences;2021-02-16